A joke about bald heads by comedian and presenter Chris Rock at the Oscars ceremony last month stung patients and providers of alopecia areata (AA) around the world. Actor Will Smiths shocking slap to Rocks face in response ignited public awareness of a disorder that steals the hair of nearly 7 million people in the United States, many of them children.
But the emotionally challenging and disfiguring autoimmune disease that prompted actor Jada Pinkett Smith, the jokes target, to shave her head and her husband, Will Smith, to react, has been on the radar of dermatology clinicians and researchers at the University of Colorado Anschutz Medical Campus for years.
Like many providers who care for patients who suffer from AA, Stanca Birlea, MD, PhD, was saddened by the widely publicized fiasco. Patients with extensive or long duration alopecia areata can be severely impacted with their disease, and they need to be approached and treated with special understanding and empathy, said Birlea, an associate professor in the Department of Dermatology at the University of Colorado School of Medicine.
For now, no cure exists, but therapy options leading to improved outcomes are expanding. Birlea and her colleagues are particularly excited about one of the latest class of drugs added to their arsenal called JAK inhibitors, she said.
Pioneering work at CU Anschutz focuses on these drugs, some given off-label to patients in its dermatology clinic and others being tested in clinical trials. All have been described as remarkable and life-changing by patients and providers.
AA, a common autoimmune disorder that affects 0.1-0.2% of the general population, causes either sudden diffuse hair loss or circular bald patches of the scalp. The condition most often targets the scalp but can cause hair loss anywhere on the body.
Over 200,000 new cases are diagnosed every year in the United States, affecting both sexes. While it can arise at any age, 80% of cases are diagnosed before age 40, with 50% of cases diagnosed in childhood. AA can have devastating consequences in all patients, but especially in children, Birlea said.
Half of alopecia areata cases strike in childhood, when school peers often lack sensitivity and tact. The emotional stress for families can be heartbreaking.
Up to a quarter of patients have a family history of AA and/or other autoimmune diseases, with thyroid disease and vitiligo the most common. Birlea specializes in vitiligo, the disorder that caused white spots on the skin of pop legend Michael Jackson.
Atopic eczema (the most common form of eczema, which tends to run in families), is often associated with AA. AA is also prevalent in patients with Down syndrome, and faculty at the CU School of Medicine and at the Linda Crnic Institute for Down Syndrome have identified interesting clinical and molecular aspects characterizing this association, Birlea said.
Between 10% and 50% of AA patients can have nail abnormalities, including nail pitting (pinpoint depressions) and ridging (narrow raised bands) in the nail plate.
In AA, cytotoxic CD8+ T cells attack the lower segment of the hair follicles (which is called the bulb and produces the hair shaft). These T cells attack the pigment cells called melanocytes and release cytokines and chemokines, which disrupt the normal function and gradually destroy the hair follicles, Birlea said.
Genetic factors are strongly involved in the pathogenesis of AA, as suggested by heritability in first-degree relatives. Twin studies, family-based linkage studies, genome-wide association studies and candidate gene association studies have also highlighted the genetic link.
Numerous genome-wide association studies and linkage studies conducted in the last two decades have provided compelling evidence for the implication of several AA susceptibility genes, most of them with immune function, Birlea said.
Both the onset and recurrences of AA can be triggered by different factors, such as emotional stress, trauma, viral infection and hormonal changes, she said.
AA is usually asymptomatic. Some patients, however, have described burning sensation, itchiness or discomfort preceding or during the active period of hair loss, Birlea said.
The patchy AA is the most common clinical presentation. It generally affects the scalp but can affect facial hair, including beard area, and/or eyebrows and/or eyelashes. While regrowth can occur spontaneously in the bald spots, often with white hairs, new spots can appear simultaneously.
Other more severe but uncommon presentations are:
Numerous lifetime recurrences are common in more than 30% of patients. Long-duration AA creates significant frustration in patients and often has mental health consequences, including loss of self-esteem, anxiety and depression, Birlea said.
Patchy alopecia areata is the most common of the different types. The hair-loss disorder affects women and men.
Especially in the early stages, spontaneous hair regrowth can occur, and an estimated 20% of patients can have one episode of hair loss with no recurrence during their lifetimes, Birlea said.
No available treatments are curative. However, the hair follicle stem cell populations are preserved in AA, and hair follicles can be regenerated. Thus, hair regrowth can occur even years after total hair loss, with or without treatment.
Topical treatments include high-potency steroids with anti-inflammatory properties and Minoxidil (Rogaine) a vasodilator with regenerative effects on the hair follicle.
Intralesional injections of corticosteroids are another popular option that can be given monthly, Birlea said. The hair regrowth effect can be temporary, however. And the injections cannot stop onset of new bald spots in other areas, because they treat the inflammation just on the area we inject.
Topical treatments and intralesional injections can induce hair regrowth in patchy AA or in more severe types, alone or in combination with systemic medications.
Immunotherapy uses sensitizer compounds (squaric acid dibutyl ester, diphenylcyclopropenone) that cause an allergic contact dermatitis in the lesional area. They have shown success in inducing hair regrow in patchy AA, including more extensive disease.
Providers generally reserve systemic therapy for patients with severe disease that is difficult to treat, including AA with more than 20% hair loss, rapid hair loss, chronic hair loss and/or with severe distress.
Oral steroids for short periods in combination with immunosuppressive medication given long duration (like methotrexate), are sometimes prescribed, although less so with the approval of oral JAK inhibitors, in light of their numerous side effects, Birlea said.
Research on mouse and human hair follicles showed that topical and oral new drugs for AA that inhibit the Janus kinase (JAK) family of enzymes, known as JAK inhibitors reawaken the dormant follicles and prevent alopecia areata flares by blocking inflammatory signaling downstream IFN- and the T cell effects.
Three such JAK inhibitors already approved by the U.S. Food and Drug Administration are Jakafi(Ruxolitinib), a medication that is used to treat bone marrow malignancies, and Olumiant (Baricitinib) and Xelijanz(Tofiacitinib), both medications for rheumatoid arthritis.
In a study of severe AA patients treated with oral Xelijanz for four to 24 months, 74.3% of patients showed clinical response, and 51.4% showed greater than 50% hair regrowth. Those results could not be achieved with the standard treatments, indicating that this is a major clinical research breakthrough, Birlea said.
JAK inhibitors can provide excellent results, inducing significant or full hair regrowth, even in those patients who have been resistant to standard therapies or have been having long-standing disease. Stanca Birlea, MD, PhD
Several clinical trials are underway on JAK inhibitors, including through the dermatology department with Birlea and her alopecia areata expert colleagues: Cory A. Dunnick, MD, professor and director of clinical trials; David Norris, MD, professor and department chair; and Elizabeth Wallace, MD, assistant professor and associate director of clinical trials.
Dunnick is leading a trial of a phase 3, open-label, multicenter study looking at the long-term safety and efficacy of an oral JAK inhibitor for alopecia areata.
Facial hair, eyebrows and eyelashes can be targets of AA. Treatments options include topical, oral and injections.
Dunnick, Norris and Wallace are also part of a National Institutes of Health-funded study on the use of JAK inhibitors for five skin diseases common in patients with Down syndrome (including alopecia areata) and led by Joaquin Espinosa, PhD, professor of pharmacology and executive director at the Linda Crnic Institute for Down Syndrome.
The study aims are to:
While JAK inhibitors are promising, the treatment option is mostly symptomatic, with hair loss typically reoccurring within months of the discontinuation of therapy, Birlea said. For this reason, providers recommend it long term, trying to maintain patients on the minimum effective dose, she said.
"JAK inhibitors can provide excellent results, inducing significant or full hair regrowth, even in those patients who have been resistant to standard therapies or have been having long-standing disease, Birlea said. This outcome can have a profoundly positive effect on affected patients quality of life.
Original post:
Will Smith's Slap at the Oscars Awakens the World to Alopecia Areata - University of Colorado Anschutz Medical Campus
- Glowing embryonic gecko hand and otherworldly slime mold amaze in winning microscope photos - Livescience.com - October 13th, 2022
- Sierra Space, UC San Diego Partner to Develop the First Stem Cell Research Institute in Space - Business Wire - October 4th, 2022
- Second-Line BCL Treatment Landscape Shifts From ASCT to CAR T-Cell Therapy - Targeted Oncology - October 4th, 2022
- CellResearch Corporation reports positive results of DFU trial - Labiotech.eu - September 25th, 2022
- University of Colorado's ocular stem cell and regenerative research program recognized - Ophthalmology Times - September 8th, 2022
- RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies - GlobeNewswire - August 22nd, 2022
- Patient Profile 1: A 63-Year-Old Female with Relapsed Multiple Myeloma - OncLive - August 22nd, 2022
- Stem Cell Therapy: Update and Clinical Research 2022 - August 14th, 2022
- The engineer who teaches our bodies to heal themselves - EL PAS USA - July 19th, 2022
- Control in Healthcare: History and Reclamation of Bodily Autonomy - Non Profit News - Nonprofit Quarterly - July 19th, 2022
- This Simple Fish May Have Been One of the First Vertebrates - The Scientist - July 11th, 2022
- How Tumor Cells Use Mitochondria to Keep Growing - July 3rd, 2022
- Nearly 75 Percent Of Veterinarians Concerned That Frequent Injections Could Cause Joint Damage - Horse Racing News - Paulick Report - July 3rd, 2022
- OEDIT Announces Recipients of Collaborative Infrastructure Grant - Colorado Office of Economic Development and International Trade - June 22nd, 2022
- Politics Briefing: Conservative leadership race is intense, Bergen says, but she expects party unity once it's over - The Globe and Mail - June 13th, 2022
- Maine health care workers to appeal order to disclose their names in vaccine mandate lawsuit - Press Herald - June 4th, 2022
- America's return to the 19th century - York Dispatch - June 4th, 2022
- Top 10 Most Popular Stem Cell Treatments of 2022 - April 19th, 2022
- Northern Colorado Doctor Researching New Treatment Options ... - December 24th, 2021
- Christmas Wish: 4-year-old just wants life-saving treatment for her twin brother - FOX 31 Denver - December 24th, 2021
- Breakthrough infections might not be a big transmission risk. Heres the evidence. - WBEZ - October 16th, 2021
- The race to treat a rare, fatal syndrome may help others with common disorders like diabetes - Science Magazine - February 14th, 2021
- Stem Cell Therapy Market Size, Top Key Players, Applications, Business Statistics, Trends and Forecast 2021-2027 The Bisouv Network - The Bisouv... - February 7th, 2021
- More on deadly blizzards | TheFencePost.com - Fence Post - February 7th, 2021
- 'A heart of gold': Rick Schwartz remembered for his commitment to family, community - CTV News - November 13th, 2020
- Alex Trebek died of pancreatic cancer think twice before saying he lost his battle with the disease - MarketWatch - November 13th, 2020
- Culprit Mutations, Risky (Neandertal) Variants, Genomic Analysis App: COVID-19 Updates - Bio-IT World - October 7th, 2020
- Stem Cell Therapy Market Size, Analytical Overview, Key Players, Growth Factors, Demand, Trends And Forecast to 2027 - thedailychronicle.in - September 30th, 2020
- Cancer Stem Cells Market is Thriving Worldwide 2020-2027 | Top Companies Merck KGaA, ONCOMED PHARMACEUTICALS INC, Bionomics, MacroGenics, Inc.,... - September 9th, 2020
- 27 De-Stressing Vegan Products to Help You Get Through The Rest of 2020 - VegNews - September 9th, 2020
- THE BONDS OF FRIENDSHIP: OXFORD AND SUNWAY - The Star Online - September 9th, 2020
- Colorados juvenile prisons have avoided COVID-19 outbreaks, but advocates worry about the future - The Denver Post - May 30th, 2020
- Future Leader Winner Using Technology To Solve The Problems He Sees - CBS Denver - May 30th, 2020
- SONDERMANN | Is it time to send a scientist to the Senate? - coloradopolitics.com - April 18th, 2020
- 5 Things to Know About Hemp-CBD In Pet Products - The Fresh Toast - April 18th, 2020
- Alone, together: Isolation in the name of health is familiar - Coloradoan - March 24th, 2020
- Stem Cell Therapy Colorado - thriveMD Denver & Vail, CO - March 20th, 2020
- Little Tissue, Big Mission: Beating Heart Tissues to Ride Aboard The ISS - Newswise - March 9th, 2020
- Denver Regenerative Medicine & Stem Cell Therapy - March 1st, 2020
- 5 most popular innovation stories in Houston this week - InnovationMap - January 5th, 2020
- Chiropractor Denver Announces Hormone Replacement Therapy Colorado Springs to Transform Life of Aging People - Press Release - Digital Journal - November 24th, 2019
- Cord Blood Banking Services Market size with global investment, top companies analysis, new business developments and forecast 2025 - Montana Ledger - November 16th, 2019
- Stem Cell Therapy - Boulder, Colorado | Boulder Biologics |Jason Glowney, MD | Stem Cells - Denver, Colorado | PRP | Regenerative Medicine | EPAT |... - May 20th, 2019
- Stem Cells and Hearing Loss - Sound Relief Hearing Center - May 1st, 2019
- Stem Cell Therapy - Boulder, Colorado | Boulder Biologics ... - April 20th, 2019
- Stem Cell Therapy for Joint Pain and Soft Tissue, Colorado - April 12th, 2019
- Stem Cells from Fat vs. Bone Marrow Best Sources for ... - April 7th, 2019
- CROM Stem Cell Therapy- Denver, Colorado - March 27th, 2019
- Gene expression in stem cells | Data Nuggets - March 7th, 2019
- Denver Stem Cell | Area's Leading Stem Cell Doctors - February 22nd, 2019
- Stem Cell Therapy - Colorado Springs Orthopaedic Group - January 16th, 2019
- Using Stem Cells to Treat Sepsis - Stem Cell Centers, Colorado - November 28th, 2018
- Stem Cell Fraud | Colorado Stem Cell Therapy - November 23rd, 2018
- Colorado Stem Cell Therapy | Home - October 1st, 2018
- FAQ | Colorado Stem Cell Therapy - October 1st, 2018
- Stem Cell Therapy | Spine & Joint Solutions - Colorado Springs - July 29th, 2018
- In Depth About Regenerative Therapy | Regen Colorado - July 25th, 2018
- Pepsi: Aborted Baby Cells in Drink Research | Colorado ... - July 15th, 2018
- Stem Cell Therapy in Colorado | Aspen Integrative Medicine - June 23rd, 2018
- Stem Cell Therapy Denver Colorado - Colorado Rehabilitation - June 18th, 2018
- Stem Cell PRP Therapy | Colorado Stem Cell Therapy - June 18th, 2018
- Stem Cell Therapy - Colorado Springs Orthopedics - October 14th, 2017
- Top Stem Cell Therapy Clinic in Vail & Denver, Colorado ... - September 25th, 2017
- 'Little Frankenstein,' conceived so Minnesota doctors could save sister, is now a happy teen - Minneapolis Star Tribune - June 25th, 2017
- What happens when scientists leave their labs to experiment with politics? - Los Angeles Times - June 21st, 2017
- Regenexx: injections soon will replace orthopedic surgery - Broomfield Enterprise - June 21st, 2017
- How a simple cheek swab can save a life - FOX31 Denver - June 4th, 2017
- Ground broken on new $US65 million facility at Colorado State University - Horsetalk - June 4th, 2017
- SpaceX to launch CU-built heart, bone health experiments to space station - CU Boulder Today - June 4th, 2017
- Translational Medicine Institute launched at Colorado State University - Source - June 4th, 2017
- Giraffe 'sneakers' in use at the Cheyenne Mountain Zoo! - KKTV 11 News - May 24th, 2017
- For the first time ever, researchers produced lab-grown blood stem cells - Colorado Springs Gazette - May 24th, 2017
- Chattanooga Student Surprised to be a Gift of Life Donor - WDEF News 12 - May 24th, 2017
- Is Autologous Heamatopoietic Stem Cell Transplantation Still Viable for MS? - LWW Journals - May 19th, 2017
- Stem Cell Transplants May Work for MS, Study Says - LWW Journals (blog) - April 20th, 2017
- 'Priming' protein boosts stem cell response to injury, promotes healing - FierceBiotech - April 20th, 2017
- Overcoming Opioids: The quest for less addictive drugs - Colorado Springs Gazette - April 20th, 2017
- Climbing mountains for cancer research - The Wilton Bulletin - April 20th, 2017
- Australian of the Year Alan Mackay-Sim on the advantage of being 'an interested scientist' - The Sydney Morning Herald - April 9th, 2017
- Northern Colorado Surgeon Releases Three Year Results of Bone Marrow Stem Cell Treatment - PR Web (press release) - April 5th, 2017